AADI BIOSCIENCES
(NASDAQ: AADI)
Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai in November 2007 and is headquartered in Los Angeles, CA.
3.390
+1.070
(+46.12%)
Range
2.070 - 3.600
(73.91%)
Open
2.520
Previous Close
2.320
Bid Price
8.140
Bid Volume
8
Ask Price
8.200
Ask Volume
30
Volume
8,803,871
Value
-
Remark
View All Events
Loading Chart...
Please login to view stock data and analysis